Company: STAA
Filing Date: 2025-10-09
Form Type: DFAN14A
Source: 0001213900-25-097833
Chunk: 14

Company: STAAR SURGICAL CO
Filing Date: 2025-10-09
Form: DFAN14A
Chunk 14
---
 17 Years and £28 Billion
Later. “Putting pressure on the committee, going on talking about ‘I need the prize, I’m the worthy candidate’
— it’s not a very peaceful approach.” People Are Already Lining Up to Rent the Crypto Torture Townhouse.

<div align='center'>Exhibit 2-5</div>

Exhibit 3

Glass Lewis recommends against STAAR–Alcon merger, bolstering Broadwood’s campaign

Investing.com

Author: Luke Juricic

Published 10/09/2025, 08:58 AM

Investing.com -- The proxy war between STAAR Surgical
Company (NASDAQ:STAA) and its largest shareholder, Broadwood Partners, has reached a fever pitch this week after influential proxy advisory
firm Glass Lewis & Co. recommended that shareholders vote against the proposed $28-per-share sale of STAAR to Alcon AG (NYSE:ALC).

The report marks a watershed moment in the months-long
standoff, aligning the proxy giant with Broadwood and fellow dissenters Yunqi Capital and Defender Capital in arguing that the deal undervalues
the company, was rushed through under questionable circumstances, and may be tainted by conflicts of interest.

The recommendation represents a monumental win
for Broadwood, which has led a relentless campaign to block the sale since its announcement in August. Together with Yunqi, Defender,
and other outspoken holders, including CalSTRS and former CEO David Bailey, the opposing parties now represent over 34% of STAAR’s
outstanding shares, an amount that could determine the fate of the $1.5 billion merger when shareholders vote at a special meeting on
October 23.

With Glass Lewis siding squarely with the activists,
and Institutional Shareholder Services (ISS) still to weigh in, the outcome of the shareholder vote has shifted from routine approval
to open uncertainty.

A sale at half the price of earlier offers

In April 2024, STAAR rejected a $58-per-share
bid from Alcon, which later withdrew a $55 offer with a $7 contingent value right (CVR). Yet, after a year of collapsing Chinese sales
and a battered stock price, STAAR’s board agreed to sell for just $28 per share, a decision Broadwood has called “indefensible.”
STAAR’s board has continually defended the deal, pointing out a 59% premium to its 90-day average trading price prior to the announcement.

STAAR, a California-based medical device